The invention relates to an anti-
cancer sustained release injection, consisting of sustained release microspheres and menstruum, wherein, the sustained release microspheres comprise sustained release auxiliary material,
angiogenesis inhibitor and / or proteolytic
enzyme; and the menstruum contains suspending agent. The
angiogenesis inhibitor is selected from
gefitinib,
erlotinib,
lapatinib, vatalanib, pelitinib,
endostatin,
imatinib, semaxanib,
dasatinib, avastin,
sorafenib,
sunitinib, telcyta or panitumumab; the proteolytic
enzyme is selected from one or the combination of
collagenase,
hyaluronidase,
relaxin and plasmase; the sustained release auxiliary material is selected from polifeprosan,
decanedioic acid copolymer, EVAc,
polylactic acid, the mixture or the
copolymer thereof, and the like; and the suspending agent is selected from
carboxymethyl cellulose and the like with the
viscosity of 100cp to 3000cp (under the temperature of 25 DEG C to 30 DEG C). The injection can also be made into a sustained release
implant. The sustained release injection is injected or arranged in or around the tumour and can improve the local
drug concentration selectively, reduce the general reaction of the
drug, inhibit the growth of tumour
cell and
blood vessel and enhance the
treatment effect of non-operative treatments, such as radiotherapy,
chemotherapy, etc.